• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Bohemine

Bohemine

Product ID B5728
Cas No. 189232-42-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $75.00 In stock
5 mg $211.00 In stock
25 mg $717.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Bohemine is a purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhibits anticancer activity. Bohemine suppresses cell growth and induces G1 and G2 phase cell cycle arrest in hybridoma cells.

Product Info

Cas No.

189232-42-6

Purity

≥98%

Formula

C18H24N6O

Formula Wt.

340.43

Chemical Name

3-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol 

IUPAC Name

3-{[6-(Benzylamino)-9-isopropyl-9H-purin-2-yl]amino}-1-propanol

Synonym

3-{[6-(benzylamino)-9-(propan-2-yl)-9h-purin-2-yl]amino}propan-1-ol; CHEMBL83980; CHEBI:86007 

Solubility

>17mg/ml in DMSO

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B5728 MSDS PDF

Info Sheet

B5728 Info Sheet PDF

References

Kovarova H, Halada P, Man P, et al. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PMID: 12625783.

Franek F, Strnad M, Havlícek L, et al. Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma culture. Cytotechnology. 2001 Jul;36(1-3):117-23. PMID: 19003322.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B9200

    BX-795

    PDK1 inhibitor.

    ≥98%
  • S0048

    Salicin

    Alcoholic β-glucoside found in willow bark, sa...

    ≥98%
  • B1853

    1,4-Benzoquinone

    Precursor in the synthesis of hydroquinone, ant...

    ≥98%
  • M9634

    Myriocin

    Atypical amino acid found in Isaria sinclairi, ...

    ≥99%, TLC
  • C7997

    C-Type Natriuretic Peptide (1-22), human

    Endogenous cardiomodulatory peptide; NPR-B agon...

    ≥95%
  • H9726

    Hygromycin B

    Protein translocation inhibitor.

    ≥95.0%
  • B1655

    S-(N-Benzylthiocarbamoyl)-L-cysteine

    Cysteine conjugate of benzyl isothiocyanate (BI...

    ≥98%
  • B1855

    O6-Benzylguanine

    MGMT inhibitor.

    ≥98%
  • T176503

    Temsirolimus

    Analog of rapamycin.

    ≥98%
  • G4581

    Glucosamine Sulfate Potassium Chloride

    Endogenous amino acid sugar involved in cartila...

    ≥98%
  • C4757

    Clozapine

    M4 mAChR agonist, 5-HT1A partial agonist, M1/2/...

    ≥97%
  • A0833

    Acipimox

    Niacin derivative.

    ≥98%
  • P6959

    Prothionamide

    Nicotinic acid derivative; InhA inhibitor.

    ≥98%
  • C1644

    Celecoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • T8006

    Tubastatin A Hydrochloride

    HDAC6/10 inhibitor.

    ≥98%
  • S4932

    SMI-4a

    Thiazolidine; Pim kinase inhibitor.

    ≥99%
  • T7034

    Trimethoprim

    Dihydrofolate reductase inhibitor.

    ≥98%
  • P2856

    Phorbol-12,13-dibutyrate

    PKC and PKD activator, carcinogen.

    ≥98%
  • R0248

    Ramatroban

    CRTH2 inhibitor, TxA2 antagonist.

    ≥98%
  • K624760

    KPT-276

    CRM1/XPO1 inhibitor.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only